Madrigal Pharmaceuticals (MDGL) Stock Statistics & Valuation Metrics

Madrigal Pharmaceuticals has a market cap or net worth of $6.79B. The enterprise value is $5.96B.

Madrigal Pharmaceuticals has 22.08M shares outstanding. The number of shares has decreased by -2.65% in one year.

Madrigal Pharmaceuticals’s return on equity (ROE) is -0.62 and return on invested capital (ROIC) is -56.90%.

The current PE Ratio of Madrigal Pharmaceuticals is -14.09. Madrigal Pharmaceuticals’s PEG ratio is -1.47.

In the last 12 months, Madrigal Pharmaceuticals had revenue of $180.13M and earned -$465.89M in profits. Earnings per share was -$21.90.

In the last 12 months, operating cash flow was -$455.57M and capital expenditures -$6.46M, giving a free cash flow of -$462.03M billion.

Madrigal Pharmaceuticals pays an annual dividend of , resulting in a dividend yield of

Madrigal Pharmaceuticals upcoming earnings date is May 13, 2025, TBA.

Madrigal Pharmaceuticals as a current ratio of 6.10, with Debt / Equity ratio of <0.01

In the past 12 months, Madrigal Pharmaceuticals has paid $0.00 in taxes.

Madrigal Pharmaceuticals EV to EBITDA ratio is -14.36, with an EV/FCF ratio of -14.15.

Madrigal Pharmaceuticals has $926.25M in cash and marketable securities with $119.57M in debt, giving a net cash position of -$806.68M billion.

Gross margin is 96.54%, with operating margin of -276.39%, and net profit margin of -258.64%.

The average price target for Madrigal Pharmaceuticals is $413.87, which is 11.43% higher than the current price. The consensus rating is Strong Buy